Sanofi Elitek Phase IV Studies Will Examine Risk Of Allergic Reactions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase IV commitments for Sanofi-Synthelabo’s Elitek are intended to better identify the risk of allergic reactions associated with the hyperuricemia treatment.